ArticleClinical and vaccine immunology : CVI2012
Human endogenous retrovirus K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected in HIV-1-infected subjects using standard peptide matrix-based screening.
Article in Clinical and vaccine immunology : CVI, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Interactions between human immunodeficiency virus and human endogenous retroviruses.Journal of virology · 2025Review
- HIV-1 infection activates endogenous retroviral promoters regulating antiviral gene expression.Nucleic acids research · 2020Article
- Telescope: Characterization of the retrotranscriptome by accurate estimation of transposable element expression.PLoS computational biology · 2019Article
- Modulation of human endogenous retrovirus (HERV) transcription during persistent and de novo HIV-1 infection.Retrovirology · 2015Article
- Regulation of the human endogenous retrovirus K (HML-2) transcriptome by the HIV-1 Tat protein.Journal of virology · 2014Article
- Human endogenous retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods.Journal of negative results in biomedicine · 2013Article
- Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system.PloS one · 2013Article
- HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates.The Journal of clinical investigation · 2012Article
- Expression of human endogenous retrovirus type K (HML-2) is activated by the Tat protein of HIV-1.Journal of virology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 3 countries.
Funding
Abstract
T-cell responses to human endogenous retrovirus (HERV) K(HML-2) Gag and Env were mapped in HIV-1-infected subjects using 15 mer peptides. Small peptide pools and high concentrations were used to maximize sensitivity. In the 23 subjects studied, only three bona fide HERV-K(HML-2)-specific responses were detected. At these high peptide concentrations, we detected false-positive responses, three of which were mapped to an HIV-1 Gag peptide contaminant. Thus, HERV-K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected by 15 mer peptide mapping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.